Biomedical Engineering Reference
In-Depth Information
migration towards gliomas. Furthermore, the tropism of these hMSCs for
gliomas may be mediated by specific growth factors/chemokines. It was also
observed that murine MSCs transfected with epidermal growth factor receptor
(EGFR) could enhance migratory responses toward glioma-conditioned media
in comparison to primary MSCs in vitro. Enhanced migration of EGFR-MSC
may be partially dependent on EGF-EGFR, PI 3-kinase, MAP kinase, protein
kinase C, and actin polymerization.
50
Another in vivo test indicated that MSCs
can localize to human gliomas either after regional intra-arterial delivery or
after local intracranial delivery.
11
It was also reported that intravenous
injection of MSC-IFN-b cells into mice with established MDA 231 or A375SM
pulmonary metastases led to the incorporation of MSCs in the tumor
architecture.
9
However, in the healthy organs examined, no engraftment of
intravenously administered MSCs was observed,
9
indicating MSCs themselves
may not cause side effects in the healthy organs.
Compared with the tumor-targeted nanocarrier systems, which simply
involves the ligand-receptor interaction, more factors are implicated in the
homing of MSCs to tumor sites, and therefore a higher tumor target efficiency
of MSCs would be expected (Figure 12.3). However, the processes and factors
d
n
4
y
3
n
g
|
1
Figure 12.3
Schematic diagram of nanocarrier systems and MSCs for site-targeted
drug/gene delivery (modified from Tanaka et al.
5
and Chen et al.
67
). FR:
folate receptor; EGFR: epidermal growth factor receptor.
